-
公开(公告)号：CA2872216C
公开(公告)日：2021-07-20
申请号：CA2872216
申请日：2013-06-25
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： ROMBOUTS FREDERIK JAN RITA , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS , LANGLOIS XAVIER JEAN MICHEL , VANHOOF GRETA CONSTANTIA PETER , ANDRES-GIL JOSE IGNACIO , DE ANGELIS MERI , BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS , TRABANCO-SUAREZ ANDRES AVELINO
IPC: A61K31/4985 , A61K31/5025 , C07D487/04
Abstract: The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051342 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1- aryl-4-methyl- [1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.
-
公开(公告)号：HUE050665T2
公开(公告)日：2020-12-28
申请号：HUE16812961
申请日：2016-12-16
Applicant: JANSSEN PHARMACEUTICA NV
-
公开(公告)号：AU2016374568B2
公开(公告)日：2020-08-27
申请号：AU2016374568
申请日：2016-12-16
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： ANDRES-GIL JOSE IGNACIO , VAN GOOL MICHIEL LUC MARIA , BORMANS GUY MAURITS R , VERBEEK JOOST
IPC: C07D487/04 , A61K51/04 , A61K101/02 , C07B59/00
Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
-
公开(公告)号：EA030426B1
公开(公告)日：2018-08-31
申请号：EA201592252
申请日：2014-06-03
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： VAN GOOL MICHIEL LUC MARIA , ALONSO-DE DIEGO SERGIO-ALVAR , CID-NUNEZ JOSE MARIA , DELGADO-GONZALEZ OSCAR , DECORTE ANNELIES MARIE ANTONIUS , MACDONALD GREGOR JAMES , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS , TRABANCO-SUAREZ ANDRES AVELINO , GARCIA-MOLINA ARANZAZU , ANDRES-GIL JOSE IGNACIO
IPC: C07D487/04 , A61K31/4985 , A61P25/00
Abstract: Изобретениеотноситсяк новымпроизводным 6,7-дигидропиразоло[1,5-а]пиразин-4(5Н)-онаформулы (I)вкачествеотрицательныхаллостерическихмодуляторов (NAM) метаботропныхглутаматныхрецепторовподтипа 2 ("mGluR2"). Изобретениетакженаправленонафармацевтическиекомпозиции, содержащиетакиесоединения, наспособыполучениятакихсоединенийи композицийи наприменениетакихсоединенийи композицийдляпредупрежденияилилечениярасстройств, вкоторыевовлеченыметаботропныерецепторыподтипа mGluR2, вособенностирасстройств CNS.
-
公开(公告)号：UA117016C2
公开(公告)日：2018-06-11
申请号：UAA201513103
申请日：2014-06-03
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： VAN GOOL MICHIEL LUC MARIA , ALONSO-DE DIEGO SERGIO-ALVAR , CID-NUNEZ JOSE MARIA , DELGADO-GONZALEZ OSCAR , DECORTE ANNELIES MARIE ANTONIUS , MACDONALD GREGOR JAMES , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS , TRABANCO-SUAREZ ANDRES AVELINO , GARCIA-MOLINA ARANZAZU , ANDRES-GIL JOSE IGNACIO
IPC: C07D487/04 , A61K31/4985 , A61P25/00
Abstract: Данийвинахідстосуєтьсяновихпохідних 6,7-дигідропіразоло[1,5-а]піразин-4(5Н)-онуформули (І) якнегативнихалостеричнихмодуляторів (NAM) метаботропнихглутаматнихрецепторівпідтипу 2 (mGluR2). Данийвинахідтакожнаправленийнафармацевтичнікомпозиції, щомістятьтакісполуки, наспособиодержаннятакихсполуктакомпозиційтаназастосуваннятакихсполуктакомпозиційдляпопередженняаболікуваннярозладів, вякізалученіметаботропнірецепторипідтипу mGluR2, зокремарозладів CNS.
-
Patent Agency Ranking
公开(公告)号：AU2016374568A1
公开(公告)日：2018-05-17
申请号：AU2016374568
申请日：2016-12-16
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： ANDRES-GIL JOSE IGNACIO , VAN GOOL MICHIEL LUC MARIA , BORMANS GUY MAURITS R , VERBEEK JOOST
IPC: C07D487/04 , A61K51/04 , A61K101/02 , C07B59/00
Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
-
公开(公告)号：AU2014276963B2
公开(公告)日：2018-05-10
申请号：AU2014276963
申请日：2014-06-03
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： VAN GOOL MICHIEL LUC MARIA , ALONSO-DE DIEGO SERGIO-ALVAR , CID-NUNEZ JOSE MARIA , DELGADO-GONZALEZ OSCAR , DECORTE ANNELIES MARIE ANTONIUS , MACDONALD GREGOR JAMES , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS , TRABANCO-SUAREZ ANDRES AVELINO , GARCIA-MOLINA ARANZAZU , ANDRES-GIL JOSE IGNACIO
IPC: C07D487/04 , A61K31/4985 , A61P25/00
Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved, especially CNS disorders.
-
公开(公告)号：HUE033057T2
公开(公告)日：2017-11-28
申请号：HUE14727824
申请日：2014-06-03
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： VAN GOOL MICHIEL LUC MARIA , ALONSO-DE DIEGO SERGIO-ALVAR , CID-NUÒEZ JOSE MARIA , DELGADO-GONZALEZ OSCAR , DECORTE ANNELIES MARIE ANTONIUS , MACDONALD GREGOR JAMES , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS , TRABANCO-SUAREZ ANDRES AVELINO , GARCIA-MOLINA ARANZAZU , ANDRES-GIL JOSE IGNACIO
IPC: A61P25/00
-
公开(公告)号：CA3010690A1
公开(公告)日：2017-08-10
申请号：CA3010690
申请日：2017-02-01
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： MOECHARS DIEDERIK WILLEM ELISABETH , ROMBOUTS FREDERIK JAN RITA , LEENAERTS JOSEPH ELISABETH , ANDRES-GIL JOSE IGNACIO , FIERENS KATLEEN , CHUPAKHIN VLADIMIR , BORMANS GUY MAURITS R , DECLERCQ LIEVEN DENIS HERWIG , KOLB HARTMUTH , ZHANG WEI
IPC: A61K51/04 , C07B59/00 , C07D401/14
Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
-
公开(公告)号：CA3003962A1
公开(公告)日：2017-06-22
申请号：CA3003962
申请日：2016-12-16
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： ANDRES-GIL JOSE IGNACIO , VAN GOOL MICHIEL LUC MARIA , BORMANS GUY MAURITS R , VERBEEK JOOST
IPC: A61K51/04 , C07B59/00 , C07D487/04
Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
-
-
-
-
-
-
-
-
-
Search Results
405
records
(took 0.027 seconds)
